Xeris Pharmaceuticals Doses First Patient in Phase 2 Trial Evaluating Its Ready-to-Use Glucagon to Address Exercise-Induced Hypoglycemia
Stock Information for Xeris Biopharma Holdings Inc.
Loading
Please wait while we load your information from QuoteMedia.